Generic Name and Formulations:
Potassium citrate 5mEq (540mg), 10mEq (1080mg), 15mEq (1620mg); tabs.
Mission Pharmacal Company
Indications for UROCIT-K:
Renal tubular acidosis with calcium stones. Hypocitraturic calcium oxalate nephrolithiasis. Uric acid lithiasis.
Take within 30 minutes of meals or bedtime snack. Adjust based on urinary citrate levels and/or pH. Urinary citrate <150mg/day: 30mEq twice daily or 20mEq 3 times daily. Urinary citrate >150mEq/day: 15mEq twice daily or 10mEq 3 times daily. Max 100mEq/day.
See literature. Hyperkalemia or predisposing conditions. GI narrowing or stricture, delayed gastric emptying or predisposing conditions. Peptic ulcer disease. UTI. Renal insufficiency (GFR <0.7mL/kg per minute).
Restrict salt intake and encourage high fluid intake. Discontinue if severe vomiting, GI pain or bleeding occurs and follow-up. Monitor 24 hour urinary citrate, urinary pH, serum electrolytes, CBC, ECG, at least every 4 months; discontinue if hyperkalemia, significant rise in serum creatinine, or significant fall in hematocrit or hemoglobin occurs. Pregnancy (Cat.C). Nursing mothers.
Contraindicated with potassium-sparing diuretics, anticholinergics, other drugs that slow GI motility. Monitor digoxin. May interfere with some urinary tract antibiotics. Caution with drugs that raise serum potassium.
Hyperkalemia, GI upset, irritation, bleeding.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds